Application 761433
- Type
- BLA
- Sponsor
- JANSSEN BIOTECH
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | RYBREVANT FASPRO | AMIVANTAMAB AND HYALURONIDASE-LPUJ | INJECTION | 10ML | No | No |
| 002 | RYBREVANT FASPRO | AMIVANTAMAB AND HYALURONIDASE-LPUJ | INJECTION | 14ML | No | No |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Rybrevant Faspro | AMIVANTAMAB AND HYALURONIDASE-LPUJ (HUMAN RECOMBINANT) | Janssen Biotech, Inc. | 9e58b045-e352-4f62-99bf-77fae1bebc69 | 2026-06-17 | Warnings, Adverse reactions | BLA761433 |